NEW YORK, Dec. 16, 2013
/PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom &
Gross LLP is investigating claims on behalf of investors of Solta
Medical, Inc. ("Solta" or the "Company") (NYSE: SLTM) (ISIN:
US83438K1034) (CUSIP: 83438K103) concerning the proposed
acquisition of Solta by Valeant Pharmaceuticals International,
Inc.
The investigation concerns whether the Solta directors are
breaching their fiduciary duties by failing to adequately shop the
Company and maximize shareholder value. Under the terms of
the agreement, Solta shareholders will receive $2.92 per share in cash for each share of Solta
common stock. However, the Price to Total Assets and Revenue
multiples are below the averages of comparable transactions.
Solta shareholders seeking more information about this
acquisition are advised to contact Ofer
Ganot at oganot@pomlaw.com or 212-661-1100, ext. 315.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and San
Diego, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of defrauded
investors. See www.pomerantzlaw.com.
CONTACT:
Ofer Ganot
Pomerantz Grossman Hufford Dahlstrom
& Gross LLP
212-661-1100 ext. 315
oganot@pomlaw.com
SOURCE Pomerantz Grossman Hufford
Dahlstrom & Gross LLP